Chern-En Chiang Selected Research

Glucose (Dextrose)

1/2022	Baseline Characteristics of Patients With HF With Mildly Reduced and Preserved Ejection Fraction: DELIVER Trial.
10/2021	Efficacy of dapagliflozin in heart failure with reduced ejection fraction according to body mass index.
1/2020	Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
11/2019	Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
1/2018	2018 consensus of the Taiwan Society of Cardiology and the Diabetes Association of Republic of China (Taiwan) on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Chern-En Chiang Research Topics

Disease

31	Atrial Fibrillation 10/2022 - 12/2002
27	Stroke (Strokes) 10/2022 - 08/2012
23	Heart Failure 10/2022 - 08/2012
19	Hemorrhage 10/2022 - 02/2014
15	Ischemic Stroke 10/2022 - 10/2012
14	Hypertension (High Blood Pressure) 10/2022 - 10/2006
10	Intracranial Hemorrhages (Intracranial Hemorrhage) 01/2022 - 01/2016
9	Myocardial Infarction 10/2022 - 10/2012
8	Coronary Disease (Coronary Heart Disease) 10/2022 - 02/2014
6	Type 2 Diabetes Mellitus (MODY) 01/2022 - 11/2007
6	Hypercholesterolemia 04/2019 - 03/2008
5	Acute Coronary Syndrome 10/2022 - 01/2019
5	Tachycardia (Tachyarrhythmias) 09/2011 - 01/2003
4	Embolism (Embolus) 10/2022 - 04/2018
4	Body Weight (Weight, Body) 09/2018 - 10/2010
4	Wolff-Parkinson-White Syndrome (Wolf-Parkinson-White Syndrome) 02/2013 - 02/2004
3	Chronic Renal Insufficiency 04/2020 - 01/2015
3	Thromboembolism 01/2020 - 07/2013
3	Cardiovascular Diseases (Cardiovascular Disease) 05/2016 - 11/2007
2	Unstable Angina 10/2022 - 01/2020
2	Thrombosis (Thrombus) 01/2022 - 11/2007
2	Essential Hypertension 01/2021 - 10/2006
2	Neoplasms (Cancer) 10/2020 - 09/2013
2	Hemorrhagic Stroke 01/2019 - 08/2017
2	Proteinuria 05/2017 - 01/2015
2	Venous Thromboembolism 01/2017 - 01/2016
2	Diabetes Mellitus 05/2016 - 02/2014
2	Cardiac Arrhythmias (Arrythmia) 05/2013 - 05/2007
2	Atrioventricular Nodal Reentry Tachycardia (AV Nodal Reentrant Tachycardia) 02/2013 - 02/2005
2	Ventricular Tachycardia 10/2004 - 10/2003
2	Shock 04/2004 - 12/2002
1	Coronary Artery Disease (Coronary Atherosclerosis) 10/2022
1	Heart Diseases (Heart Disease) 01/2022
1	Frailty 01/2022
1	Cardiomyopathies (Cardiomyopathy) 06/2021
1	Cognitive Dysfunction 01/2021
1	Chronic Kidney Failure (Chronic Renal Failure) 04/2020
1	Transient Ischemic Attack 01/2020
1	Peripheral Arterial Disease 01/2020
1	Vascular Diseases (Vascular Disease) 01/2020
1	Hypotension (Low Blood Pressure) 01/2020
1	Renal Insufficiency (Renal Failure) 01/2019
1	Cerebral Hemorrhage 01/2019

Drug/Important Bio-Agent (IBA)

29	AnticoagulantsIBA 10/2022 - 08/2012
19	Vitamin K FDA Link 01/2022 - 07/2013
17	Warfarin (Coumadin)FDA LinkGeneric 01/2021 - 11/2007
11	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2022 - 10/2012
9	dapagliflozinIBA 01/2022 - 11/2019
7	SodiumIBA 10/2022 - 01/2015
7	N(4)-oleylcytosine arabinosideIBA 01/2022 - 02/2015
6	omega-Chloroacetophenone (Mace)IBA 10/2022 - 10/2012
6	alirocumabIBA 10/2022 - 01/2018
6	oxidized low density lipoproteinIBA 04/2019 - 08/2012
5	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 01/2018
5	Dabigatran FDA Link 12/2018 - 02/2015
4	edoxabanIBA 10/2022 - 02/2015
4	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 01/2022 - 07/2014
4	RivaroxabanIBA 12/2018 - 02/2015
4	LipidsIBA 03/2017 - 03/2008
3	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 05/2022 - 09/2013
3	Antihypertensive Agents (Antihypertensives)IBA 05/2022 - 10/2006
3	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 05/2022 - 10/2015
3	Angiotensin Receptor AntagonistsIBA 05/2022 - 09/2013
2	pro-brain natriuretic peptide (1-76)IBA 01/2022 - 01/2018
2	theasinensin AIBA 01/2022 - 01/2019
2	Losartan (Cozaar)FDA LinkGeneric 01/2021 - 10/2006
2	Sodium-Glucose Transport ProteinsIBA 01/2021 - 11/2019
2	Pharmaceutical PreparationsIBA 01/2021 - 04/2016
2	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2020 - 11/2019
2	apixabanIBA 12/2018 - 01/2016
2	CholesterolIBA 03/2017 - 01/2014
2	Rosuvastatin Calcium (Crestor)FDA Link 05/2016 - 03/2008
2	Digoxin (Digitek)FDA LinkGeneric 10/2015 - 10/2014
2	Adenosine Triphosphate (ATP)IBA 04/2004 - 12/2002
1	Sodium Chloride Symporter Inhibitors (Diuretics, Thiazide)IBA 05/2022
1	4- (2- (4- hydroxybenzyl)- phenoxy)- N- methylbutylamineIBA 05/2022
1	Brain Natriuretic Peptide (Natrecor)FDA Link 01/2022
1	Natriuretic PeptidesIBA 01/2022
1	SymportersIBA 10/2021
1	Oxygen (Dioxygen)IBA 06/2021
1	Myosins (Myosin)IBA 06/2021
1	Cardiac MyosinsIBA 06/2021
1	Carvedilol (Coreg)FDA LinkGeneric 03/2021
1	Indicators and Reagents (Reagents)IBA 01/2021
1	rostafuroxinIBA 01/2021
1	Valsartan Drug Combination Amlodipine FDA Link 10/2020
1	Hypoglycemic Agents (Hypoglycemics)IBA 07/2020
1	CanagliflozinIBA 04/2020
1	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2020
1	ORALIT (ORS)IBA 12/2018

Therapy/Procedure

23	Therapeutics 05/2022 - 12/2002
9	Catheter Ablation 05/2013 - 12/2002
3	Secondary Prevention 01/2019 - 04/2016
2	Percutaneous Coronary Intervention 01/2022 - 05/2018
2	Dental Scaling 10/2013 - 04/2013
1	Denervation 05/2022
1	Drug Therapy (Chemotherapy) 01/2022
1	Stents 01/2022
1	Drug Tapering 01/2019
1	Glycemic Control 09/2018